Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules
- 1 August 1996
- journal article
- clinical trial
- Published by Springer Nature in The Italian Journal of Neurological Sciences
- Vol. 17 (4) , 267-276
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Immunological Fluctuations During Intrathecal Immunotherapy in Three Patients Affected by CNS Tumours Disseminating Via CSFInternational Journal of Neuroscience, 1994
- Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cellsCancer Immunology, Immunotherapy, 1993
- Delayed neurotoxicity of intraventricular interleukin-2: A case reportJournal of Neuro-Oncology, 1993
- Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factorJournal of Neuro-Oncology, 1992
- Expression of Platelet-Derived Growth Factors, Transforming Growth Factors, and the ros Gene in a Variety of Primary Human Brain TumorsNeurosurgery, 1991
- Expression of platelet-derived growth factors, transforming growth factors, and the ros gene in a variety of primary human brain tumorsNeurosurgery, 1991
- Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.Journal of Clinical Investigation, 1990
- Natural killer function in flow cytometryJournal of Immunological Methods, 1989
- Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrierJournal of Neurosurgery, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987